We are live on
!
Find out more
KCM
Kalehua Capital Management Portfolio holdings
AUM
$174M
This Fund
S&P 500
This Quarter
Est. Return
+45.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$174M
AUM Growth
+$32.6M
(+23%)
Cap. Flow
+$3.44M
Cap. Flow
% of AUM
1.98%
Top 10 Holdings %
Top 10 Hldgs %
70.75%
Holding
33
New
8
Increased
3
Reduced
2
Closed
7
Avg Time Held
1.1
quarters
Top 10 Avg Time Held
1.3
quarters
Top 20 Avg Time Held
1.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$5.95M |
| 2 |
InflaRx
IFRX
|
+$5.45M |
| 3 |
KRSA
Korsana Biosciences, Inc. Common Stock
KRSA
|
+$5.36M |
| 4 |
Korro Bio
KRRO
|
+$3.67M |
| 5 |
ANL
Adlai Nortye Group ADS
ANL
|
+$2.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$8.97M |
| 2 |
ORKA
Oruka Therapeutics
ORKA
|
+$5.81M |
| 3 |
uniQure
QURE
|
+$5.54M |
| 4 |
PepGen
PEPG
|
+$1.77M |
| 5 |
Tenaya Therapeutics
TNYA
|
+$1.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.78% |
| 2 | Miscellaneous | 15.22% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Alpha Architect 1-3 Month Box ETF
BOXX
$14.6B
| $26.5M | 15.22% |
226,188
+7,910
| +4% | +$923K |
2025 Q4
2 quarters
|
|
|
MANE
2
Veradermics Inc
MANE
$5.47B
| $17.9M | 10.3% |
145,695
| – | – |
2026 Q1
1 quarter
|
|
3
X4 Pharmaceuticals
XFOR
$289M
| $17.4M | 9.99% |
3,722,840
| – | – |
2025 Q4
2 quarters
|
|
|
CMPS
4
Compass Pathways
CMPS
$1.66B
| $11.6M | 6.67% |
819,692
| – | – |
2025 Q4
2 quarters
|
|
5
Surrozen
SRZN
$349M
| $10M | 5.75% |
385,178
| – | – |
2025 Q4
2 quarters
|
|
6
Aclaris Therapeutics
ACRS
$564M
| $9.69M | 5.57% |
1,832,365
| – | – |
2026 Q1
1 quarter
|
|
|
SION
7
Sionna Therapeutics
SION
$222M
| $8.67M | 4.98% |
197,072
| – | – |
2025 Q4
2 quarters
|
|
8
Inhibikase Therapeutics
IKT
$275M
| $7.76M | 4.46% |
3,821,890
| – | – |
2025 Q4
2 quarters
|
|
9
Pharvaris
PHVS
$2.18B
| $6.87M | 3.95% |
198,772
| – | – |
2025 Q4
2 quarters
|
|
|
10
Karyopharm Therapeutics
KPTI
$13.7M
| $6.7M | 3.85% |
+685,644
| New | +$5.95M |
2026 Q2
0 quarters
|
|
|
SEPN
11
Septerna Inc
SEPN
$1.79B
| $6.52M | 3.75% |
194,544
| – | – |
2025 Q4
2 quarters
|
|
|
12
InflaRx
IFRX
$236M
| $6.49M | 3.73% |
+2,897,769
| New | +$5.45M |
2026 Q2
0 quarters
|
|
|
KRSA
13
Korsana Biosciences, Inc. Common Stock
KRSA
$1.54B
| $5.6M | 3.22% |
+235,907
| New | +$5.36M |
2026 Q2
0 quarters
|
|
|
14
Korro Bio
KRRO
$150M
| $5.34M | 3.07% |
405,040
+295,664
| +270% | +$3.67M |
2026 Q1
1 quarter
|
|
|
15
uniQure
QURE
$1.57B
| $3.66M | 2.1% |
79,407
-211,702
| -73% | -$5.54M |
2026 Q1
1 quarter
|
|
|
LONA
16
LeonaBio Inc
LONA
$54.2M
| $3.62M | 2.08% |
393,701
| – | – |
2025 Q4
2 quarters
|
|
|
DMRA
17
Damora Therapeutics
DMRA
$1.3B
| $3.62M | 2.08% |
139,000
| – | – |
2026 Q1
1 quarter
|
|
18
MoonLake Immunotherapeutics
MLTX
$921M
| $3.42M | 1.97% |
175,734
| – | – |
2025 Q4
2 quarters
|
|
|
ANL
19
Adlai Nortye Group ADS
ANL
$1.01B
| $2.6M | 1.5% |
+226,415
| New | +$2.76M |
2026 Q2
0 quarters
|
|
20
Tyra Biosciences
TYRA
$1.37B
| $2.38M | 1.37% |
74,465
| – | – |
2025 Q4
2 quarters
|
|
21
Nuvectis Pharma
NVCT
$689M
| $1.84M | 1.06% |
+100,000
| New | +$1.12M |
2026 Q2
0 quarters
|
|
22
Gossamer Bio
GOSS
$56.9M
| $1.84M | 1.05% |
139,367
+11,413
| +9% | +$255K |
2026 Q1
1 quarter
|
|
23
Milestone Pharmaceuticals
MIST
$95.2M
| $1.7M | 0.98% |
+1,269,237
| New | +$2.03M |
2026 Q2
0 quarters
|
|
|
ATYR
24
aTyr Pharma
ATYR
$24.1M
| $1.07M | 0.61% |
+1,788,167
| New | +$1.17M |
2026 Q2
0 quarters
|
|
25
Instil Bio
TIL
$45.7M
| $766K | 0.44% |
99,600
-83,430
| -46% | -$673K |
2026 Q1
1 quarter
|
|
Similar funds
PWSG
6SA
NWA
PIA
CPCP
PMSA
MCM
AIA
Kalehua Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Kalehua Capital Management held 33 positions worth $174M, up 23% from $141M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Kalehua Capital Management's Q2 2026 filing shows 8 new, 3 increased, 2 reduced and 7 closed positions. Its largest new stake was Karyopharm Therapeutics: 685,644 shares worth $6.7M. The largest sale was Relay Therapeutics, an estimated $8.97M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Materials.
- Kalehua Capital Management's largest Q2 2026 buy was Karyopharm Therapeutics: 685,644 shares worth $6.7M.
- Kalehua Capital Management added most to Korro Bio in Q2 2026, an estimated $3.67M increase.
- Kalehua Capital Management's biggest Q2 2026 reduction was uniQure, cutting an estimated $5.54M.
- Kalehua Capital Management fully exited Relay Therapeutics in Q2 2026, selling an estimated $8.97M.
- Kalehua Capital Management's ten largest holdings make up 71% of its $174M portfolio in Q2 2026.
- Kalehua Capital Management opened 8 new positions and closed 7 in Q2 2026.
- Kalehua Capital Management's portfolio value rose 23% quarter-over-quarter to $174M.
Based on Kalehua Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.